Novartis ESMO Event Presentation
PSMAfore met primary endpoint¹ with clinically meaningful and
highly statistically significant rPFS benefit in pre-taxane setting
1
Pluvicto demonstrated robust efficacy...
✓ More than doubled median rPFS2
Consistent benefit across subgroups²
✓ Improved QoL compared to daily oral ARPI²
✓ Pre-specified crossover-adjusted OS
analysis HR 0.802
2
... with a favorable safety profile
Lower rate of Grade ≥3 AEs compared
to daily oral ARPI
Low rate of AE-driven discontinuations
✓ Fewer patients required dose adjustment
Even better tolerability than in VISION
1. Primary rPFS analysis based on centrally confirmed rPFS events with Oct. 2022 data cutoff. 2. Updated rPFS analysis (at time of 2nd interim OS analysis) based on Jun. 2023 data cutoff.
9
NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION
NOVARTIS | Reimagining MedicineView entire presentation